NEW YORK, December 8, 2016 /PRNewswire/ --
Today, Stock-Callers.com monitors the most recent performances of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), and INSYS Therapeutics Inc. (NASDAQ: INSY). Over the ten years to 2021, industry value added growth in the global Biotech segment is expected to grow 3.5% per year on average, slightly greater than the annualized global GDP growth of 2.7% over the same period. The rapid acceleration in demand reflects the significant expansion in the products supplied by the industry. Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
http://stock-callers.com/registration
Aurinia Pharma
On Wednesday, shares Canada headquartered Aurinia Pharmaceuticals Inc. recorded a trading volume of 480,122 shares. The stock ended the session 4.61% lower at $2.90. The Company's shares have gained 12.40% in the last one month, 34.88% over the previous three months, and 17.41% on an YTD basis. The stock is trading 0.51% above its 200-day moving average. Moreover, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have a Relative Strength Index (RSI) of 39.58.
On November 21st, 2016, Aurinia Pharmaceuticals announced highlights from its global Phase IIb AURA study of voclosporin in the treatment of lupus nephritis (LN) presented at the American Society of Nephrology Kidney Week 2016. The AURA study enrolled 265 patients in 20 countries using low dose (23.7 mg BID) voclosporin, high dose voclosporin (39.5 mg BID) or placebo added to standard of care of mycophenolate mofetil (MMF) and steroids in active LN. The study met its primary endpoint with statistically significant CR rates in the 23.7mg BID arm. The AURA study remains ongoing until its 48-week secondary endpoints, which will be completed in Q1 2017. Visit us today and access our complete research report on AUPH at:
http://stock-callers.com/registration/?symbol=AUPH
Threshold Pharma
South San Francisco, California headquartered Threshold Pharmaceuticals Inc.'s stock closed the day flat at $0.46, with a total trading volume of 569,035 shares. The Company's shares have advanced 21.05% in the past month. The stock is trading 9.59% below its 50-day moving average. Additionally, shares of Threshold Pharma, which discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the US, have an RSI of 46.33.
On November 7th, 2016, Threshold Pharma reported that no revenue was recognized in Q3 2016, compared to $3.7 million for Q3 2015. The company posted net loss for Q3 2016 of $5.7 million, compared to $6.4 million for Q3 2015. Cash, cash equivalents, and marketable securities totaled $28.1 million at September 30th, 2016, compared to $33.6 million at June 30th, 2016. The complimentary report on THLD can be downloaded at:
http://stock-callers.com/registration/?symbol=THLD
Regeneron Pharma
Shares in New York headquartered Regeneron Pharmaceuticals Inc. recorded a trading volume of 1.68 million shares, which was higher than their three months average volume of 842,730 shares. The stock ended yesterday's trading session 1.88% lower at $362.01. The Company's shares are trading below their 50-day moving average by 5.86%. Furthermore, shares of Regeneron Pharma, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 36.59.
In a SEC filing dated November 25th, 2016, Regeneron Pharmaceuticals entered into a Termination Agreement relating to the Master Terms and Conditions for Warrants, dated as of October 18th, 2011, with Morgan Stanley & Co. International PLC on November 18th, 2016. The Morgan Stanley Warrant Agreement governed the remaining outstanding warrants issued by the Company to Morgan Stanley in 2011 in connection with the issuance of Regeneron's 1.875% convertible senior notes and the related hedging transactions. Pursuant to the Termination Agreement, the remaining number of warrants held by Morgan Stanley has been reduced to zero and the Morgan Stanley Warrant Agreement has been terminated effective upon the payment by the Company to Morgan Stanley of an aggregate amount of $33.5 million. Register for free on Stock-Callers.com and access the latest research report on REGN at:
http://stock-callers.com/registration/?symbol=REGN
INSYS Therapeutics
Arizona headquartered INSYS Therapeutics Inc.'s stock finished Wednesday's session 4.80% lower at $10.70. A total volume of 842,360 shares was traded, which was higher than their three months average volume of 738,500 shares. The Company's shares are trading below their 50-day moving average by 11.27%. Additionally, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 38.27.
On November 3rd, 2016, INSYS Therapeutics reported Q3 2016 total net revenue of $55.2 million, compared to $91.3 million for Q3 2015. The company's net income for the reported quarter totaled $190,000, or $0.00 per basic and $0.00 per diluted share, compared to net income of $26.1 million, or $0.36 per basic and $0.34 per diluted share for Q3 2015. Get free access to your research report on INSY at:
http://stock-callers.com/registration/?symbol=INSY
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Advertisement
Today, Stock-Callers.com monitors the most recent performances of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), and INSYS Therapeutics Inc. (NASDAQ: INSY). Over the ten years to 2021, industry value added growth in the global Biotech segment is expected to grow 3.5% per year on average, slightly greater than the annualized global GDP growth of 2.7% over the same period. The rapid acceleration in demand reflects the significant expansion in the products supplied by the industry. Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
Advertisement
http://stock-callers.com/registration
Aurinia Pharma
On Wednesday, shares Canada headquartered Aurinia Pharmaceuticals Inc. recorded a trading volume of 480,122 shares. The stock ended the session 4.61% lower at $2.90. The Company's shares have gained 12.40% in the last one month, 34.88% over the previous three months, and 17.41% on an YTD basis. The stock is trading 0.51% above its 200-day moving average. Moreover, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have a Relative Strength Index (RSI) of 39.58.
On November 21st, 2016, Aurinia Pharmaceuticals announced highlights from its global Phase IIb AURA study of voclosporin in the treatment of lupus nephritis (LN) presented at the American Society of Nephrology Kidney Week 2016. The AURA study enrolled 265 patients in 20 countries using low dose (23.7 mg BID) voclosporin, high dose voclosporin (39.5 mg BID) or placebo added to standard of care of mycophenolate mofetil (MMF) and steroids in active LN. The study met its primary endpoint with statistically significant CR rates in the 23.7mg BID arm. The AURA study remains ongoing until its 48-week secondary endpoints, which will be completed in Q1 2017. Visit us today and access our complete research report on AUPH at:
http://stock-callers.com/registration/?symbol=AUPH
Threshold Pharma
South San Francisco, California headquartered Threshold Pharmaceuticals Inc.'s stock closed the day flat at $0.46, with a total trading volume of 569,035 shares. The Company's shares have advanced 21.05% in the past month. The stock is trading 9.59% below its 50-day moving average. Additionally, shares of Threshold Pharma, which discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the US, have an RSI of 46.33.
On November 7th, 2016, Threshold Pharma reported that no revenue was recognized in Q3 2016, compared to $3.7 million for Q3 2015. The company posted net loss for Q3 2016 of $5.7 million, compared to $6.4 million for Q3 2015. Cash, cash equivalents, and marketable securities totaled $28.1 million at September 30th, 2016, compared to $33.6 million at June 30th, 2016. The complimentary report on THLD can be downloaded at:
http://stock-callers.com/registration/?symbol=THLD
Regeneron Pharma
Shares in New York headquartered Regeneron Pharmaceuticals Inc. recorded a trading volume of 1.68 million shares, which was higher than their three months average volume of 842,730 shares. The stock ended yesterday's trading session 1.88% lower at $362.01. The Company's shares are trading below their 50-day moving average by 5.86%. Furthermore, shares of Regeneron Pharma, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 36.59.
In a SEC filing dated November 25th, 2016, Regeneron Pharmaceuticals entered into a Termination Agreement relating to the Master Terms and Conditions for Warrants, dated as of October 18th, 2011, with Morgan Stanley & Co. International PLC on November 18th, 2016. The Morgan Stanley Warrant Agreement governed the remaining outstanding warrants issued by the Company to Morgan Stanley in 2011 in connection with the issuance of Regeneron's 1.875% convertible senior notes and the related hedging transactions. Pursuant to the Termination Agreement, the remaining number of warrants held by Morgan Stanley has been reduced to zero and the Morgan Stanley Warrant Agreement has been terminated effective upon the payment by the Company to Morgan Stanley of an aggregate amount of $33.5 million. Register for free on Stock-Callers.com and access the latest research report on REGN at:
http://stock-callers.com/registration/?symbol=REGN
INSYS Therapeutics
Arizona headquartered INSYS Therapeutics Inc.'s stock finished Wednesday's session 4.80% lower at $10.70. A total volume of 842,360 shares was traded, which was higher than their three months average volume of 738,500 shares. The Company's shares are trading below their 50-day moving average by 11.27%. Additionally, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 38.27.
On November 3rd, 2016, INSYS Therapeutics reported Q3 2016 total net revenue of $55.2 million, compared to $91.3 million for Q3 2015. The company's net income for the reported quarter totaled $190,000, or $0.00 per basic and $0.00 per diluted share, compared to net income of $26.1 million, or $0.36 per basic and $0.34 per diluted share for Q3 2015. Get free access to your research report on INSY at:
http://stock-callers.com/registration/?symbol=INSY
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
